

April 29, 2021



Calyxt Successfully Transforms Hemp Genome

New Hemp Transformation Technology Unlocks Capabilities to Selectively Breed and Deliver Improvements in Hemp Traits for Key Markets Including Protein, Fiber, Advanced Materials and Wellness Patent-Pending Transformation Process is Calyxt's First Announced Innovation in a Broad Hemp Improvement Pipeline

ROSEVILLE, MN / ACCESSWIRE / April 29, 2021/ [Calyxt, Inc.](#) (NASDAQ:CLXT), a plant-based technology company, announced today that it has successfully transformed hemp genome, enabling a step-change in innovation approaches in the species. This transformation technology enables future advancements in hemp such as trait delivery, gene editing and advanced plant breeding and is expected to accelerate hemp variety development.

Hemp, a historically non-domesticated crop, is not yet adapted for broad-acre production agriculture. Out of reach by U.S. farmers and seed breeders for nearly 80 years, hemp has not benefited from modern breeding and genomics advances - until now. Calyxt is enabling improvements in identified plant behaviors and traits, which will allow hemp breeders to select new varieties that will establish it as a modern, stable and valuable broad-acre crop to be positioned at the forefront of agricultural opportunity.

"The hemp species as a whole has historically been a particularly difficult crop to transform," said Travis Frey, Ph.D., chief technology officer with Calyxt. "We overcame the technical hurdles presented by this crop in under a year thanks to our world-class team of experts skilled in applying innovative tissue culture and DNA delivery to achieve this milestone. This transformation opens the door to other advancements in hemp through gene editing."

Calyxt's first efforts are focused on standardizing the crop for broad-acre adoption, reduced risk hemp production and modernizing the breeding process. Calyxt anticipates its innovations will initially come to market as breeding platform tools or licensed traits and be commercialized by leading germplasm and hemp-based ingredient and material companies.

"This is our first delivery of innovation from our platform of hemp improvement tools that leverages decades of work and learning from other crop species," said Sarah Reiter, vice president of business development with Calyxt. "This tool delivers capabilities to selectively breed and make improvements in hemp traits, including, but not limited to protein, fiber, advanced materials and wellness. Calyxt is leveraging its proprietary plant transformation technologies to accelerate hemp innovation and is exploring collaboration opportunities with partners looking to leverage our technology to add to their programs in hemp."

About Calyxt

[Calyxt](#) (NASDAQ:CLXT), based in Roseville, Minnesota, is a technology company with a

mission to deliver plant-based innovations for a better world. Founded in 2010, Calyxt uses its proprietary TALEN® gene editing technology to work with world-class partners to revolutionize the way the world uses plants to solve problems. For further information, please visit our website at www.calyxt.com.

Forward-Looking Statements

This communication contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as "anticipates," "believes," "continue," "estimates," "expects," "targets," "intends," "may," "might," "plans," "potential," "predicts," "projects," "should," or "will," the negative of these terms and other similar terminology. Forward-looking statements in this press release include statements about our ideation and product development efforts, our business model and go-to-market strategies, and growth strategies. These and other forward-looking statements are predictions and projections about future events and trends based on our current expectations, objectives and intentions and premised on current assumptions. Our actual results, level of activity, performance, or achievements could be materially different than those expressed, implied, or anticipated by forward-looking statements due to a variety of factors, including, but not limited to: the severity and duration of the evolving COVID-19 pandemic and the resulting impact on macro-economic conditions; the impact of increased competition; disruptions at our or our collaborators' key facilities; changes in customer preferences and market acceptance of our or our partners' products; competition for collaboration partners and licensees and the successful execution of collaborations and licensing agreements; the impact of adverse events during development; the impact of improper handling of our product candidates by unaffiliated third parties during development; failures by third-party contractors; inaccurate demand forecasting; the effectiveness of commercialization efforts by commercial partners or licensees; our ability to collect accounts receivable; commodity price conditions; the impact of changes or increases in oversight and regulation; disputes or challenges regarding intellectual property; proliferation and continuous evolution of new technologies; management changes; dislocations in the capital markets; and other important factors discussed under the caption entitled "Risk Factors" in our most recent Annual Report on Form 10-K and subsequent filings on Form 10-Q or 8-K with the U.S. Securities and Exchange Commission. Any forward-looking statements made by us are based only on information currently available to us when, and speaks only as of the date, such statement is made. Except as otherwise required by securities and other applicable laws we do not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change.

For further information, please contact:

Calyxt Media Contact:

Trina Lundblad, Director of Corporate Communications
(612) 790-0514
media@calyxt.com

Calyxt Investor Relations Contact:

Chris Tyson, Managing Director
MZ Group - MZ North America
(949) 491-8235

CLXT@mzgroup.us
www.mzgroup.us

SOURCE: Calyxt

View source version on accesswire.com:

<https://www.accesswire.com/643200/Calyxt-Successfully-Transforms-Hemp-Genome>